Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its ...
NasoVAX intranasal influenza vaccine demonstrated strong cellular immune response and 100% seroprotection HepTcell vaccine was well tolerated but T-cell immunogenicity results were inconclusive GAITHERSBURG, Md., March 27, 2018 (GLOBE NEWSWIRE) -- …